A multi-billion-dollar acquisition within the radiopharmaceutical space could be percolating as Lantheus Holding considers a buyout offer from Curium Pharma, Bloomberg
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Months after reports first linked Curium to a potential Lantheus takeover, the radiopharma players have made it official with a…
Curium acquires Lantheus for $102.5/share (~$8B); Sandoz settles price-fixing for $478.5M; Latigo eyes $247M IPO for non-opioid…
La société Curium Pharma spécialisée dans la radiothérapie vient d'annoncer le rachat de Lantheus, un autre acteur du secteur.…
Negócio, com conclusão prevista para o primeiro semestre de 2027, inclui direitos de valor contingente atrelados ao portfólio…
CapVest-backed Curium agrees to acquire Lantheus for up to $8B, expanding its global footprint in nuclear medicine.
Two growing companies, Supernus Pharmaceuticals and Indivior Pharmaceuticals, have
